• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

myotonic dystrophy Type 1

Desert sand dunes
Research

RNA-targeting drug relaxes muscles in myotonic dystrophy mice

Arrakis’ small molecule was also able to restore normal RNA splicing in muscle cells derived from patients.
Darren Incorvaia Dec 4, 2024 7:00am
Novartis

Novartis signs $1.1B deal for muscular dystrophy biotech

Nov 21, 2024 8:19am
steps race jump stairs climb

PepGen gains a little pep in its step as FDA clears trial hold

Oct 12, 2023 7:00am
Letter opening FDA clinical hold

Awaiting FDA letter, PepGen oligonucleotide no closer to clinic

Jun 14, 2023 9:05am
Stop sign

FDA blocks PepGen's attempt to get 2nd oligonucleotide to clinic

May 31, 2023 8:11am
Photo of a chain being held together by a piece of rope

Avidity says FDA has 'eased' partial hold on lead asset

May 17, 2023 11:16am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings